F10 and Stroke: Although the differences in stroke severity may be explained by the underlying risk profiles between patients receiving FXa inhibitor and warfarin, previous studies have suggested smaller ICH volume, less hematoma expansion, and fewer concomitant intraventricular hemorrhage in patients with ICH taking non–vitamin K OACs.8,15,16 Importantly, in certain clinical scenarios, such as atrial fibrillation with recent percutaneous coronary intervention, patients may be required to take both anticoagulant and antiplatelet agents for secondary prevention.